Login
$GRCE
$1.75 -$0.06 (3.31%) Live

Company Executives

Officer Age In this role Joined 2026 pay Source
Prashant Kohli Also a director
Chief Executive Officer
54 Not stated Not stated $1,270,820
Robert DelAversano
Principal Financial Officer
Title from the Form 4 dated Aug 28, 2026
55 Not stated 2023 Not reported
R. Loch Macdonald
Chief Medical Officer
65 Since 2023
3 years
Not stated Not reported
Amresh Kumar
Vice President, Program Management
47 Since 2023
3 years
Not stated $465,650

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
5
serving now
Independent
4 of 4
stated in the proxy; 1 not stated
Average tenure
3.4 years
from year joined
CEO also chairs the board
No
Vimal Kavuru
Director Age On board Independent Committees Other public boards 2026 pay Source
Vimal Kavuru
57 2021
5 years
Independent
Compensation Committee · Chair Nominating and Corporate Governance Committee · Chair
None stated $124,467
Prashant Kohli
54 2023
3 years
Not stated None stated None stated Paid as CEO
A. Brian Davis
59 2023
3 years
Independent None stated None stated $89,467
S. George Kottayil
63 2023
3 years
Independent None stated None stated $65,467
Edward Neugeboren
57 2023
3 years
Independent None stated Matinas Biopharma, Inc. $81,467

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Jul 28, 2026
Shore Pharma LLC
an entity held in a trust for the benefit of immediate family members of Vimal Kavuru, the Chair of the Company's Board of Directors
Amount not stated
2025

Purchase of common stock, 2025 Pre-Funded Warrants and 2025 Common Warrants in the 2025 Private Placement.

With the Company Open in proxy
ADAR1 Partners, LP, AIGH Investment Partners, LP, and SS Pharma LLC
each a beneficial owner of more than 5% of the common stock prior to the 2025 Private Placement
Approximately $5.7 million
2025

Purchase of common stock, 2025 Pre-Funded Warrants and 2025 Common Warrants in the 2025 Private Placement; the stated gross proceeds are an aggregate for all related parties in the placement.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support